Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.57 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.56 |
| ▸ | NPY4R | P50391 | 5/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.54 |
| ▸ | NPY1R | P25929 | 4/20 | 0.54 |
| ▸ | NPY2R | P49146 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524262 | 0.96 | EPHA2 (0.59) | EPHA2NTSR2NTSR1SORT1NPY4R | |
| SCHEMBL13807693 | 0.95 | NTSR2 (0.56) | EPHA2NTSR2NTSR1SORT1NPY4R | |
| SCHEMBL13807701 | 0.92 | EPHA2 (0.57) | EPHA2NTSR2NTSR1NPY4RNPY5R | |
| SCHEMBL31257023 | 0.90 | EPHA2 (0.57) | EPHA2NTSR2NTSR1SORT1 | |
| SCHEMBL13816930 | 0.89 | NPY4R (0.60) | NTSR2NTSR1SORT1NPY4RNPY5R | |
| SCHEMBL9807256 | 0.88 | EPHA2 (0.59) | EPHA2NTSR2NTSR1SORT1 | |
| SCHEMBL30038002 | 0.88 | NPY4R (0.59) | NPY4RNPY5RNPY1RNPY2ROPRM1 | |
| SCHEMBL30454832 | 0.87 | EPHA2 (0.57) | EPHA2NTSR2NTSR1SORT1 | |
| SCHEMBL31410846 | 0.86 | EPHA2 (0.58) | EPHA2NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL9807245 | 0.86 | EPHA2 (0.61) | EPHA2NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156507-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | CUREGENICS LTD. | 2009-06-18 | — | — | US | disclosed |
| US-20070078092-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | CUREGENICS LTD. (IL) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078092-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | MAP3K20, MAP3K19, MAP4K2 | EPHA2 557/4885NTSR2 1235/4885NTSR1 1169/4885 |
| US-20090156507-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | MAP3K20, MAP3K19, MAP4K2 | EPHA2 557/4885NTSR2 1235/4885NTSR1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.